Co-delivery strategies based on multifunctional nanocarriers for cancer therapy

Current Drug Metabolism

Volumn 13, Issue 8, 2012, Pages 1087-1096

  Chen, Hao ^a   Zhao, Ying ^b   Wang, Hai ^b   Nie, Guangjun ^b   Nan, Kaihui ^a  

^a EYE HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^b NATIONAL CENTER FOR NANOSCIENCE AND TECHNOLOGY   (China)

Author keywords

Co delivery of drugs; Multifunctional nanoparticles; Nanotechnology; Targeting

Indexed keywords

DENDRIMER; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORESCENT DYE; GREEN FLUORESCENT PROTEIN; LIPOSOME; LONIDAMINE; MULTIDRUG RESISTANCE PROTEIN 1; NANOCARRIER; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; PACLITAXEL; PLASMID DNA; POLYAMIDOAMINE; PROTEIN P53; PYRROLIDINE DITHIOCARBAMATE; QUANTUM DOT; RECOMBINANT VASCULOTROPIN; SILICON DIOXIDE; SMALL INTERFERING RNA; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE;

BIOCOMPATIBILITY; BREAST METASTASIS; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GENE THERAPY; CELL METABOLISM; CYTOTOXICITY; DRUG DELIVERY SYSTEM; FLUORESCENCE IMAGING; GENE SILENCING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MICELLE; MULTIDRUG RESISTANCE; NANOTECHNOLOGY; NONHUMAN; OVARY CANCER; REVIEW; RNA INTERFERENCE; STATIC ELECTRICITY;

ANIMALS; ANTINEOPLASTIC AGENTS; CONTRAST MEDIA; DNA; DRUG CARRIERS; GENETIC THERAPY; HUMANS; NANOPARTICLES; NEOPLASMS; PROTEINS; RNA, SMALL INTERFERING; TISSUE DISTRIBUTION;

EID: 84868033291     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920012802849995     Document Type: Review

References (86)

1. Cho, K.; Wang, X.; Nie, S.; Chen, Z. (G.); Shin, D.M. Therapeutic Nanoparticles for Drug Delivery in Cancer. Clin. Cancer Res., 2008, 14, 1310-1316.
2. Ross, J.S.; Schenkein, D.P.; Pietrusko, R.; Rolfe, M.; Linette, G.P.; Stec. J.; Stagliano, N.E.; Ginsburg, G.S.; Symmans, W.F.; Pusztai, L.; Hortobagyi, G.N. Targeted therapies for cancer 2004. Am. J. Clin. Pathol., 2004, 122, 598-609.
3. Morgillo, F.; Lee, H.Y. Resistance to epidermal growth factor receptor-targeted therapy. Drug Resist. Updat., 2005, 8, 298-310.
4. Maeda, H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme. Regul., 2001, 41, 189-207.
5. Allen, T.M. Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer, 2002, 2, 750-763.
6. Zhang, L.; Radovic-Moreno, A.F.; Alexis, F.; Gu, F.X.; Basto, P.A.; Bagalkot, V.; Jon, S.; Langer, R.S.; Farokhzad, O.C. Co-Delivery of Hydrophobic and Hydrophilic Drugs from Nanoparticle-Aptamer Bioconjugates. Chem. Med. Chem., 2007, 2, 1268-1271.
7. Kost, J.; Langer, R. Responsive polymeric delivery systems. Adv. Drug Delivery Rev., 2001, 46, 125-148.
8. Moghimi, S.M.; Szebeni, J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid Res., 2003, 42, 463-478.
9. Peppas, N.A.; Hilt, J.Z.; Khademhosseini, A.; Langer, R. Hydrogels in biology and medicine: from molecular principles to bionanotechnology. Adv. Mater., 2006, 18, 1345-1360.
10. Farokhzad, O.; Langer, R. Nanomedicine: Developing smarter therapeutic and diagnostic modalities. Adv. Drug Delivery Rev., 2006, 58, 1456-1459.
11. Aluri, S.; Janib, S.M.; Mackay, J.A. Environmentally responsive peptides as anticancer drug carriers. Adv. Drug Delivery Rev., 2009, 61, 940-952.
12. Gerweck, L.E.; Seetharaman, K. Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. Cancer Res., 1996, 56, 1194-1198.
13. Cook, J.A.; Gius, D.; Wink, D.A.; Krishna, M.C.; Russo, A.; Mitchell, J.B. Oxidative stress, redox, and the tumormicroenvironment. Semin. Radiat. Oncol., 2004, 14, 259-266.
14. Mbeunkui, F.; Johann Jr., D.J. Cancer and the tumor microenvironment: a review of an essential relationship. Cancer Chemother. Pharmacol., 2009, 63, 571-582.
15. Carmeliet, P.; Jain, R.K. Angiogenesis in cancer and other diseases. Nature, 2000, 407, 249-257.
16. Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release, 2000, 65, 271-284.
17. Langer, R. Drug delivery and targeting. Nature, 1998, 392, 5-10.
18. Minko, T.; Dharap, S.S.; Pakunlu, R.I.; Wang, Y. Molecular targeting of drug delivery systems to cancer. Curr. Drug Targets, 2004, 5, 389-406.
19. Sharom, J.R.; Bellows, D.S.; Tyers, M. From large networks to small Molecules. Curr. Opin. Chem. Biol, 2004, 8, 81-90.
20. Kaelin, W.G. Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer, 2005, 5, 689-698.
21. Keith, C.T.; Borisy, A.A.; Stockwell, B.R.; Multicomponent therapeutics for networked systems. Nat. Rev. Drug Discov., 2005, 4, 71-78.
22. Leha, J.; Krueger, A.S.; Avery, W.; Heilbut, A.M.; Johansen1, L.M.; Price E.R.; Rickles, R.J.; Short, G.F.; Staunton, J.E.; Jin, X.; Lee, M.S.; Zimmermann, G.R.; Borisy, A.A. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat. Biothchnol., 2009, 27, 659-670.
23. Farr, M.; Bacon, P.A. How and when should combination therapy be used? The role of an anchor drug. Br. J. Rheumatol, 1995, 34, 100-103.
24. Ahmed, F.; Pakunlu, R.I.; Brannan, A.; Bates, F.; Minko, T.; Discher, D.E. Biodegradable polymersomes loaded with both paclitaxel and doxorubicin permeate and shrink tumors by inducing apoptosis in proportion to accumulated drug. J. Control. Release, 2006, 116, 150-158.
25. Sengupta, S.; Eavarone, D.; Capila, I.; Zhao, G.; Watson, N.; Kiziltepe, T.; Sasisekharan, R. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature, 2005, 436, 568-572.
26. Briasoulis, E.; Pentheroudakis, G.; Karavasilis, V.; Tzamakou, E.; Rammou, D.; Pavlidis, N. Weekly paclitaxel combined with pegylated liposomal doxorubicin (Caelyx") given every 4 weeks: dose-finding and pharmacokinetic study in patients with advanced solid tumors. Ann. Oncol, 2004, 15, 1566-1573.
27. Gustafson, D.L.; Merz, A.L.; Long, M.E. Pharmacokinetics of combined doxorubicin and paclitaxel in mice. Cancer Lett., 2005, 220, 161-169.
28. Briasoulis, E.; Karavasilis, V.; Tzamakou, E.; Rammou, D.; Soulti, K.; Piperidou, C.; Pavlidis, N. Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel. Cancer Chemoth. Pharm., 2004, 53, 452-457.
29. Mavroudis, D.; Kouroussis, C.; Kakolyris, S.; Agelaki, S.; Kalbakis, K.; Androulakis, N.; Souglakos, J.; Samonis, G.; Georgoulias, V. Phase I Study of Paclitaxel (Taxol) and Pegylated Liposomal Doxorubicin (Caelyx) Administered Every 2 Weeks in Patients with Advanced Solid Tumors. Oncology, 2002, 62, 216-222.
30. Gehl, J.; Boesgaard, M.; Paaske, T.; Jensen, B.V.; Dombernowsky, P. Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic. Ann. Oncol, 1996, 7, 687-693.
31. Ahmed, F.; Pakunlu, R.I.; Srinivas, G.; Brannan, A.; Bates, F.; Klein, M.L.; Minko, T.; Discher, D.E. Shrinkage of a Rapidly Growing Tumor by Drug-Loaded Polymersomes: pH-Triggered Release through Copolymer Degradation. Mol. Pharmaceut., 2006, 3, 340-350.
32. Xu, X.; Chen, X.; Wang, Z.; Jing, X. Ultrafine PEG-PLA fibers loaded with both paclitaxel and doxorubicin hydrochloride and their in vitro cytotoxicity. Eur. J. Pharm. Biopharm., 2009, 72, 18-25.
33. Fan, L.; Li, F.; Zhang, H.; Wang, Y.; Cheng, C.; Li, X.; Gu, C.; Yang, Q.; Wu, H.; Zhang, S. Co-delivery of PDTC and doxorubicin by multifunctional micellar nanoparticles to achieve active targeted drug delivery and overcome multidrug resistance. Biomaterials, 2010, 31, 5634-5642.
34. Ford, J.M. Experimental reversal of P-glycoprotein-mediated multidrug resistanceresistance by pharmacological chemosensitisers. Eur. J. Cancer, 1996, 32A, 991-1001.
35. De Jong, M.C.; Slootstra, J.W.; Scheffer, G.L.; Schroeijers, A.B.; Puijk, W.C.; Dinkelberg, R.; Kool, M.; Broxterman, H.J.; Meloen, R.H.; Scheper, R.J. Peptide transport by the multidrug resistance protein MRP1. Cancer Res., 2001, 61, 2552-2557.
36. Nakanishi, C.; Toi, M. Nuclear factor-KB inhibitors as sensitizers to anticancer drugs. Nat. Rev. Cancer, 2005, 5, 297-309.
37. Brantley, E.; Patel, V.; Stinson, S.F.; Trapani, V.; Hose, CD.; Ciolino, H.P.; Yeh, G.C.; Gutkind, J.S.; Sausville, E.A.; Loaiza-Pérez, A.I. The antitumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole induces NF-kappaB activity in drug-sensitive MCF-7 cells. Anti-cancer Drug., 2005, 16, 137-143.
38. Van-Wijngaarden, J.; van-Beek, E.; van-Rossum, G.; van-der-Bent, C.; Hoekman, K.; van-der-Pluijm, G.; van-der-Pol, M.A.; Broxterman, H.J.; van-Hinsbergh, V.W.M.; Löwik, C.W.G.M. Celecoxib enhances doxorubicin-induced cytotoxicity in MDA-MB231 cells by NF-kappaB-mediated increase of intracellular doxorubicin accumulation. Eur. J. Cancer, 2007, 43, 433-442.
39. Wiradharma, N.; Tong, Y.W.; Yang, Y.-Y. Self-assembled oligopeptide nanostructures for co-delivery of drug and gene with synergistic therapeutic effect. Biomaterials, 2009, 30, 3100-3109.
40. Li, R.; Hehlman, R.; Sachs, R.; Duesberg, P. Chromosomal alterations cause the high rates and wide ranges of drug resistance in cancer cells. Cancer Genet. Cytogen., 2003, 163, 44-56.
41. Duesberg, P.; Li, R.; Sachs, R.; Fabarius, A.; Upender, M.; Hehlmann, R. Cancer drug resistance: the central role of the karyotype. Drug Resist. Update., 2003, 10, 51-58.
42. Koivusalo, R.; Krausz, E.; Helenius, H.; Hietanen, S. Chemotherapy compounds in cervical cancer cells primed by reconstitution of p53 function after short interfering RNA mediated degradation of human Papillomavirus 18 E6 mRNA: opposite effect of siRNA in combination with different drugs. Mol. Pharmacol., 2005, 68, 372-382.
43. Gjerzet, R.A.; Mercola, D. Sensitization of tumors to chemotherapy through gene therapy. Adv. Exp. Med. Biol., 2000, 465, 273-291.
44. Lee, B.D.; French, K.J.; Zhuang, Y.; Smith, C.D. Development of a syngeneic in vivo tumor model and its use in evaluating a novel P-glycoprotein modulator, PGP-4008. Oncol. Res., 2003, 14, 49-60.
45. Chen, A.M.; Zhang, M.; Wei, D.; Stueber, D.; Taratula, O.; Minko, T.; He, H. Co-delivery of Doxorubicin and Bcl-2 siRNA by Mesoporous Silica Nanoparticles Enhances the Efficacy of Chemotherapy in Multidrug-Resistant Cancer Cells. Small, 2009, 5, 2673-2677.
46. Menendez, J.A.; Vellon, L.; Colomer, R.; Lupu, R. You have full text access to this OnlineOpen articlePharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity. Int. J. Cancer, 2005, 115, 19-35.
47. Hannon, G.J.; Rossi, J.J. Unlocking the potential of the human genome with RNA interference. Nature, 2004, 431, 371-378.
48. Whitehead, K.A.; Langer, R.; Anderson, D.G. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discovery, 2009, 8, 129-138.
49. Juliano, R.; Alam, M.R.; Dixit, V.; Kang, H. Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucl. Acids Res., 2008, 36, 4158-4171.
50. Kanda, T.; Yokosuka, O.; Imazeki, F.; Arai, M.; Saisho, H. Enhanced Sensitivity of Human Hepatoma Cells to 5-Fluorouracil by Small Interfering RNA Targeting Bcl-2. DNA Cell Biol., 2005, 24, 805-809.
51. Lima, R.T.; Martins, L.M.; Guimarães, J.E.; Sambade, C.; Vasconcelos, M.H. Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells. Cancer Gene Therapy, 2004, 11, 309-316.
52. Wang, Y.; Gao, S.; Ye, W.H.; Yoon, H.S.; Yang, Y.Y. Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer. Nat. Mater., 2006, 5, 791-796.
53. Yano, J.; Hirabayashi, K.; Nakagawa, S.-i.; Yamaguchi, T.; Nogawa, M.; Kashimori, I.; Naito, H.; Kitagawa, H.; Ishiyama, K.; Ohgi, T.; Irimura, T. Antitumor Activity of Small Interfering RNA/Cationic Liposome Complex in Mouse Models of Cancer. Cancer Res., 2004, 10, 7721-7726.
54. Maszewska, M.; Leclaire, J.; Cieslak, M.; Nawrot, B.; Okruszek, A.; Caminade, A.-M.; Majoral, J.-P. Water-Soluble Polycationic Dendrimers with a Phosphoramidothioate Backbone: Preliminary Studies of Cytotoxicity and Oligonucleotide/Plasmid Delivery in Human Cell Culture. Oligonucleotides, 2003, 13, 193-205.
55. Shim, G.; Han, S.-E.; Yu, Y.-H.; Lee, S.; Lee, H.Y.; Kim, K.; Kwon, I.C.; Park, T.G.; Kim, Y.B.; Choi, Y.S.; Kim, C.-W.; Oh, Y.-K. Trilysinoyl oleylamide-based cationic liposomes for systemic co-delivery of siRNA and an anticancer drug. J. Control. Release, 2010, in press.
56. Saad, M.; Garbuzenko, O.B.; Minko, T. Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. Nanomedicine, 2008, 3, 761-776.
57. Torney, F.; Trewyn, B.G.; Lin, V.S.Y.; Wang, K. Mesoporous silica nanoparticles deliver DNA and chemicals into plants. Nat. Nanotech., 2007, 2, 295-300.
58. Zhu, C.; Jung, S.; Luo, S.; Meng, F.; Zhu, X.; Park, T.G.; Zhong, Z. Co-delivery of siRNA and paclitaxel into cancer cells by biodegradable cationic micelles based on PDMAEMA-pcl-PDMAEMA triblock copolymer. Biomaterials, 2010, 31, 2408-2416.
59. Kim, E.; Jung, Y.; Choi, H.; Yang, J.; Suh, J.-S.; Huh, Y.-M.; Kim, K.; Haam, S. Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex. Biomaterials, 2010, 31, 4592-4599.
60. Xiao, W.; Chen, X.; Yang, L.; Mao, Y.; Wei, Y.; Chen, L. Co-delivery of doxorubicin and plasmid by a novel FGFR-mediated cationic liposome. Int. J. Pharmaceut., 2010, 393, 119-126.
61. Liu, F.; Shollenberger, L.M.; Huang, L. Non-immunostimulatory nonviral vectors. FASEB J., 2004, 18, 1779-1781.
62. Chen, X.; Wang, X.H.; Wang, Y.S.; Yang, L.; Hu, J.; Xiao, W.J.; Fu, A.F.; Cai, L.L.; Li, X.; Ye, X.; Liu, Y.L.; Wu, W.S.; Shao, X.M.; Mao, Y.Q.; Wei, Y.Q.; Chen, L.J. Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide. J. Control. Release, 2010, 145, 17-25.
63. Xu, Z.; Zhang, Z.; Chen, Y.; Chen, L.; Lin, L.; Li, Y. The characteristics and performance of a multifunctional nanoassembly system for the co-delivery of docetaxel and iSur-pDNA in a mouse hepatocellular carcinoma model. Biomaterials, 2010, 31, 916-922.
64. von Maltzahn, G.; Vauthey, S.; Santoso, S.; Zhang, S. Positively charged surfactant-like peptides self-assembled into nanostructures. Langmuir, 2003, 19, 4332-4337.
65. Zhang, S. Fabrication of novel biomaterials through molecular self-assembly. Nat. Biotechnol., 2003, 21, 1171-1178.
66. Stendahl, J.C., Rao, M.S., Guler, M.O., Stupp, S.I. Intermolecular forces in the self-assembly of peptide amphiphile nanofibers. Adv. Funct. Mater. 2006, 16, 499-508.
67. Cherny, I.; Gazit, E. The bright side of amyloids: notonly pathological agents but also ordered nano-scale materials. Angew. Chem. Int. Edit., 2008, 47, 4062-4069.
68. Han, L.; Huang, R.; Li, J.; Liu, S.; Huang, S.; Jiang, C. Plasmid pORF-hTRAIL and doxorubicin co-delivery targeting to tumor using peptide-conjugated polyamidoamine dendrimer. Biomaterials, 2011, 32, 1242-1252.
69. Sinha, V.R.; Trehan, A. Biodegradable microspheres for protein delivery. J. Control. Release, 2003, 90, 261-280
70. Torchilin, V.P.; Lukyanov, A.N. Peptide and protein drug delivery to and into tumors: challenges and solutions. Drug Discov. Today, 2003, 8, 259-266.
71. Wang, X.; Yang, L.; Chen, Z.; Shin, D.M. Application of Nanotechnology in Cancer Therapy and Imaging. CA-Cancer J. Clin., 2008, 58, 97-110.
72. Lee, A.L.Z.; Wang, Y.; Cheng, H.Y.; Pervaiz, S.; Yang, Y. Y. The co-delivery of paclitaxel and Herceptin using cationic micellar Nanoparticles. Biomaterials, 2009, 30, 919-927.
73. + T cell-mediated anti-tumor immunity. Vaccine, 2008, 26, 5046-5057.
74. Gao, X.; Cui, Y.; Levenson, R.; Chung, L.; Nie, S. in vivo cancer targeting and imaging with semiconductor quantum dots. Nat. Biotechnol., 2004, 22, 969-976.
75. Lee, J.H.; Huh, Y.M.; Jun, Y.w.; Seo, J.w.; Jang, J.t.; Song, H.T.; Kim, S.; Cho, E.J.; Yoon, H.G.; Suh, J.S.; Cheon, J. Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. Nat. Med., 2007, 13, 95-99.
76. Harisinghani, MG.; Barentsz, J.; Hahn, P.F.; Deserno, W.M.; Tabatabaei, S.; van de Kaa, C.H.; de la Rosette, J.; Weissleder, R. Noninvasive detection of clinically occult lymphnode metastases in prostate cancer. N. Engl. J. Med., 2003, 348, 2491-2499.
77. Medarova, Z.; Pham, W.; Farrar, C.; Petkova, V.; Moore, A. in vivo imaging of siRNA delivery and silencing in tumors. Nat. Med., 2007, 13, 372-377.
78. Farokhzad, O.C.; Karp, J.M.; Langer, R. Nanoparticle-aptamer bioconjugates for cancer targeting. Expert Opin. Drug Deliv., 2006, 3, 311-324.
79. Nasongkla, N.; Bey, E.; Ren, J.; Ai, H.; Khemtong, C.; Guthi, J.S.; Chin, S.F.; Sherry, A.D.; Boothman, D.A.; Gao, J. Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems. Nano Lett., 2006, 6, 2427-2430.
80. Medintz, I.L.; Stewart, M.H.; Trammell, S.A.; Susumu, K.; Delehanty, J.B.; Mei, B.C.; Melinger, J.S.; Blanco-Canosa, J.B.; Dawson, P.E.; Mattoussi, H. Quantum-dot/dopamine bioconjugates function as redox coupled assemblies for in vitro and intracellular pH sensing. Nat. Mater., 2010, 9, 676-684.
81. Medintz, I.L.; Pons, T.; Delehanty, J.B.; Susumu, K.; Brunel, F.M.; Dawson, P.E.; Mattoussi, H. Intracellular Delivery of Quantum Dot-Protein Cargos Mediated by Cell Penetrating Peptides. Biocon-jugate Chem., 2008, 19, 1785-1795.
82. Verma, A.; Stellacci, F. Effect of Surface Properties on Nanoparticle-Cell Interactions. Small, 2010, 6, 12-21.
83. Milane, L.; Duan, Z.F.; Amiji, M. Pharmacokinetics and biodistribution of lonidamine/paclitaxel loaded, EGFR-targeted nanoparticles in an orthotopic animal model of multi-drug resistant breast cancer. Nanomed-Nanotechnol., 2011, 7, 435-444.
84. Kingsley, J.D.; Dou, H.; Morehead, J.; Rabinow, B.; Gendelman, H.E.; Destache, C.J. Nanotechnology: a focus on nanoparticles as a drug delivery system. J. Neuroimmune Pharmacol., 2006, 1, 340-350.
85. Wang, H.; Zhao, P.; Su, W.; Wang, S.; Liao, Z.; Niu, R.; Chang, J. PLGA/polymeric liposome for targeted drug and gene co-delivery. Biomaterials, 2010, 31, 8741-8748.
86. Wang, H.; Zhao, Y.; Wu, Y.; Hu, Y.; Nan, K.; Nie, G.; Chen H. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Biomaterials, 2011, 32, 8281-8290.